Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab Combined with Chemotherapy as Neoadjuvant Therapy for ESCC
NCT06508229Phase 2Not yet recruiting
- Sponsor
- Harbin Medical University
- Start
- Jul 2024
- Primary completion
- May 2027
- Modality
- Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of adebrelimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Harbin Medical University. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06508229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06508229.